HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kolstad, A. Articles by Torfoss, D. Search for Related Content PubMed PubMed Citation Articles by Kolstad, A. Articles by Torfoss, D.

Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen

^* Cancer Clinic, Rikshospitalet-Radiumhospitalet Medical Center, Montebello, N-0310 Oslo, Norway;
^° Medical Microbiology Laboratory, Rikshospitalet-Radiumhospitalet Medical Center, Gaustad, N-0027 Oslo, Norway

Correspondence: Arne Kolstad, Stanford University, Division of Oncology, Palo Alto, CA 94305 USA. Phone: international +650.7256456. E-mail: akolstad{at}stanford.edu

We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution. PCP prophylaxis should be standard management for this group of patients and also considered for patients treated with rituximab-CHOP-14, CHOP-14 or CHOEP-14.

This article has been cited by other articles:

				L. L. Teichmann, M. Woenckhaus, C. Vogel, B. Salzberger, J. Scholmerich, and M. Fleck Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis Rheumatology, August 1, 2008; 47(8): 1256 - 1257. [Full Text] [PDF]

				M. S. Ahmed and C. F. Wong Rituximab and nephrotic syndrome: a new therapeutic hope? Nephrol. Dial. Transplant., January 1, 2008; 23(1): 11 - 17. [Full Text] [PDF]